Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer - Wikidata - awgldk - TriplyDB

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

http://www.wikidata.org/entity/Q33429048

about

Synergism of ursolic acid and cisplatin promotes apoptosis and enhances growth inhibition of cervical cancer cells via suppressing NF-κB p65.

P2860

Q47111296-5AE0F765-F98C-4875-8E22-064429025263

P2860

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

http://www.wikidata.org/entity/Q33429048

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Feasibility study of chemoradi ...... disease small cell lung cancer

@ast

Feasibility study of chemoradi ...... disease small cell lung cancer

@en

type

label

Feasibility study of chemoradi ...... disease small cell lung cancer

@ast

Feasibility study of chemoradi ...... disease small cell lung cancer

@en

prefLabel

Feasibility study of chemoradi ...... disease small cell lung cancer

@ast

Feasibility study of chemoradi ...... disease small cell lung cancer

@en

P1433

Q33429048-49592207-C0A5-4085-AABE-E2F2E1BD8588

P1476

Q33429048-2A39C82F-5C5C-460E-91A8-2C2C1B3FF8DB

P2093

Q33429048-0646C965-3351-4786-A6BB-680A49497D66

Q33429048-202DAAE8-252B-4E6B-A154-7B8F827D7A2A

Q33429048-2BF137D5-DF4B-4F03-B935-9AA35F124DDC

Q33429048-2C5858A1-9D4C-41B3-BB1E-7C2B643DC626

Q33429048-35E6E1BD-A888-4033-8BC9-837E72CF313B

Q33429048-439A68DC-6917-40B1-89D7-2E02BDC8C4C6

Q33429048-63854BDD-67B6-4BB4-A767-4B3A5EEEC853

Q33429048-7F5D7F51-E48E-4AE1-B132-78956DC411F6

Q33429048-8E9E4CE8-04C4-46DD-B81D-2570A4896935

Q33429048-D4F398FA-545A-48A6-9DCA-A91BE5EAA62B

P2860

Q33429048-0D031627-96B1-4B55-B37A-748574425182

Q33429048-34AACF33-0417-409C-B024-6A413070C8D2

Q33429048-3737773F-ABCF-4CF6-B0C8-0CFAD1E75A92

Q33429048-43C4BA63-D854-4875-AF66-85BE89CCCFE4

Q33429048-8440F749-AEB3-4D29-B566-83746701E186

Q33429048-BAF664C5-EAAB-44B8-A551-832EAD16E939

Q33429048-CB38918A-5591-49CF-83C9-088A9A51450C

Q33429048-E5BDEB8C-F174-4B62-B30B-2A2850EC660A

Q33429048-EB4016C9-84BB-4BBA-9FBB-DC4BE98BA0C3

Q33429048-F3C7FA63-D5E2-472C-907C-857378B2AA71

P304

Q33429048-96FA65D6-BE37-4778-8D92-407CC4DD4359

P31

Q33429048-0AAB8C6D-E687-4D27-A4B0-4A22356CB0D1

P356

Q33429048-295EAA29-01CC-49FA-A5A1-3ECC755574A7

P433

Q33429048-D7572572-2B25-4EE8-B796-7887115A1431

P478

Q33429048-08E266E4-C378-4696-9486-1AB6E0426351

P577

Q33429048-3018233B-E17F-44CD-9C77-59DCC8023B7F

P698

Q33429048-02987AB7-0739-4E81-808A-0E503C3561D0

P921

Q33429048-7A398EA1-49AF-4C57-9253-BC5E6EB33C55

Q33429048-BF4D5775-C356-4858-8D6A-1DC0B861861A

P932

Q33429048-0E5DFC05-5B9A-4606-BC94-9F4F3E290E3A

P356

P1433

P1476

Feasibility study of chemoradi ...... disease small cell lung cancer

@en

P2093

Hideyuki Harada

http://www.w3.org/2001/XMLSchema#string

Ikuo Sekine

http://www.w3.org/2001/XMLSchema#string

Kayoko Tsujino

http://www.w3.org/2001/XMLSchema#string

Keiji Nihei

http://www.w3.org/2001/XMLSchema#string

Makoto Nishio

http://www.w3.org/2001/XMLSchema#string

Minako Sumi

http://www.w3.org/2001/XMLSchema#string

Miyako Satouchi

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Satoshi Ishikura

http://www.w3.org/2001/XMLSchema#string

Seiji Niho

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 s

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer.

Limited-stage small-cell lung cancer: the current status of combined-modality therapy.

Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.

P304

315-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12875

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26748638

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

Feasibility study

P932

4814250

http://www.w3.org/2001/XMLSchema#string